Sato Yasufumi
Department of Vascular Biology, Institute of Development, Aging, and Cancer, Tohoku University, 4-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
Int J Clin Oncol. 2003 Aug;8(4):200-6. doi: 10.1007/s10147-003-0342-8.
Angiogenesis is regulated by the balance of pro-angiogenic factors and angiogenesis inhibitors, and the imbalance of these regulators is the cause of pathological angiogenesis, including tumor angiogenesis. Angiogenesis is required for tumor growth and metastasis, and thus constitutes an important target for the control of tumor progression. While the benefit of anti-angiogenic therapy is potentially profound, limitations have also been recognized by the results obtained thus far by clinical trials. Precise understanding of the process of angiogenesis should lead us to new regimens for more efficient anti-angiogenic therapy. This review focuses on our current understanding of the molecular mechanism of tumor angiogenic and the status of the anti-angiogenesis approach for cancer treatment.
血管生成受促血管生成因子和血管生成抑制剂平衡的调节，这些调节因子的失衡是包括肿瘤血管生成在内的病理性血管生成的原因。血管生成是肿瘤生长和转移所必需的，因此构成了控制肿瘤进展的重要靶点。虽然抗血管生成治疗的益处可能是深远的，但临床试验迄今所取得的结果也已认识到其局限性。对血管生成过程的精确理解应能引导我们找到更有效的抗血管生成治疗新方案。本综述着重介绍我们目前对肿瘤血管生成分子机制的理解以及癌症治疗中抗血管生成方法的现状。
